• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Oncolytics Biotech President and CEO Brad Thompson steps down

Oncolytics Biotech President and CEO Brad Thompson steps down

November 4, 2016
CenterWatch Staff

Oncolytics Biotech has announced that Brad Thompson, Ph.D., has stepped down as president and chief executive officer of Oncolytics, effective immediately. The company's Chief Operating Officer Matt Coffey Ph.D., M.B.A., has been appointed interim president and chief executive officer while the company conducts a search for Dr. Thompson's replacement.

Dr. Thompson, along with Dr. Coffey, has led Oncolytics for 18 years—since it was founded. Wayne Pisano, chairman of the board of directors of Oncolytics, credited Dr. Thompson for advancing the company's lead candidate REOLYSIN in multiple cancer indications and, in particular, for the recent progress in lung, multiple myeloma and colorectal cancers.

"Dr. Thompson has been instrumental in the development of our Company and the progress we have seen in taking REOLYSIN into multiple phase II clinical trials," said Pisano. "On behalf of the board of directors, i would like to thank Brad for his dedication and leadership."

The Oncolytics board of directors is confident that Dr. Coffey will provide strong leadership and continue the development of REOLYSIN during the interim period until a new chief executive is announced. The board will be engaging an executive recruitment firm to assist it in this search process.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. 

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing